Mallinckrodt Pharmaceuticals is investing more than $21 million in an equity purchase agreement with Australia-based Mesoblast Ltd. regarding two of the company's drugs.
Under terms of the deal, Mallinckrodt will have up to nine months to conclude commercial and development agreements for Mesoblasts's therapy products used to treat chronic low back pain and acute graft versus host disease. Mallinckrodt is purchasing about 20.04 million (or 4.99 percent) of Mesoblast's shares at a price of $1.4761…
Mallinckrodt Pharmaceuticals is investing more than $21 million in an equity purchase agreement with Australia-based Mesoblast Ltd. regarding two of the company's drugs.
Under terms of the deal, Mallinckrodt will have up to nine months to conclude commercial and development agreements for Mesoblasts's therapy products used to treat chronic low back pain and acute graft versus host disease. Mallinckrodt is purchasing about 20.04 million (or 4.99 percent) of Mesoblast's shares at a price of $1.4761…